The patent relates to a mRNA/anti-PD-1 combination vaccine comprising an isolated mRNA comprising an open reading frame coding for an antigen and an antagonistic antibody directed against PD-1.
Brief outline of the case
The OD found that a new MR filed during opposition was lacking N over D1 prior art under Art 54(3).